tiprankstipranks
Advertisement
Advertisement

JBIO Stock Latest News

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
TipRanks NewswireNuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
3d ago
NVS
CRNX
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
PremiumTipRanks Newswire
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
17d ago
LLY
ABBV
Jade Biosciences Secures Exclusive Antibody License Agreement
PremiumCompany Announcements
Jade Biosciences Secures Exclusive Antibody License Agreement
25d ago
8K
JBIO
Jade Biosciences Adds Veteran Biopharma Leader to Board
PremiumCompany Announcements
Jade Biosciences Adds Veteran Biopharma Leader to Board
1M ago
8K
JBIO
BTIG says others may be interested in Apogee Therapeutics
PremiumThe Fly
BTIG says others may be interested in Apogee Therapeutics
1M ago
JNJ
NVS
Jade Biosciences initiated with a Buy at UBS
PremiumThe FlyJade Biosciences initiated with a Buy at UBS
1M ago
JBIO
Jade Biosciences Shareholders Approve Governance and Audit Measures
Premium
Company Announcements
Jade Biosciences Shareholders Approve Governance and Audit Measures
1M ago
8K
JBIO
Jade Biosciences Launches Major Underwritten Equity Offering
Premium
Company Announcements
Jade Biosciences Launches Major Underwritten Equity Offering
2M ago
8K
JBIO
JADE101 Phase 1 Trial Marks Key Early Milestone for Jade Biosciences Investors
PremiumCompany Announcements
JADE101 Phase 1 Trial Marks Key Early Milestone for Jade Biosciences Investors
2M ago
JBIO
Jade Biosciences 10M share Secondary priced at $15.00
PremiumThe Fly
Jade Biosciences 10M share Secondary priced at $15.00
2M ago
JBIO
Jade Biosciences announces common stock offering, no amount given
PremiumThe Fly
Jade Biosciences announces common stock offering, no amount given
2M ago
JBIO
Jade Biosciences price target raised to $47 from $32 at Guggenheim
PremiumThe Fly
Jade Biosciences price target raised to $47 from $32 at Guggenheim
2M ago
JBIO
Harrison Lifts JBIO Price Target to $74 on Promising JADE101 Data and Attractive IgA Nephropathy Opportunity
PremiumRatingsHarrison Lifts JBIO Price Target to $74 on Promising JADE101 Data and Attractive IgA Nephropathy Opportunity
2M ago
JBIO
Akash Tewari Initiates Buy on JBIO, Citing Strong Early JADE101 Data, Clean Safety Profile, and Significant IgA Nephropathy Commercial Upside
Premium
Ratings
Akash Tewari Initiates Buy on JBIO, Citing Strong Early JADE101 Data, Clean Safety Profile, and Significant IgA Nephropathy Commercial Upside
2M ago
JBIO
Jefferies says Jade Biosciences JADE101 data came in line with bull case
Premium
The Fly
Jefferies says Jade Biosciences JADE101 data came in line with bull case
2M ago
JBIO
Jade Biosciences Reports Positive Phase 1 JADE101 Results
PremiumCompany Announcements
Jade Biosciences Reports Positive Phase 1 JADE101 Results
2M ago
8K
JBIO
Jade Biosciences announces interim results from JADE101 trial
PremiumThe Fly
Jade Biosciences announces interim results from JADE101 trial
2M ago
JBIO
Jade Biosciences’ JADE101 Trial Opens a New Front in IgA Nephropathy Investing
PremiumCompany Announcements
Jade Biosciences’ JADE101 Trial Opens a New Front in IgA Nephropathy Investing
2M ago
JBIO
Julian Harrison Reiterates Buy on JADE101, Maintains $39 Price Target on Best‑in‑Class IgAN Potential
PremiumRatings
Julian Harrison Reiterates Buy on JADE101, Maintains $39 Price Target on Best‑in‑Class IgAN Potential
2M ago
JBIO
Jade Biosciences announces first participant dosed in JADE201 Phase 1 trial
PremiumThe FlyJade Biosciences announces first participant dosed in JADE201 Phase 1 trial
2M ago
JBIO
Jade Biosciences announces first participant dosed in Phase 2 Juniper trial
Premium
The Fly
Jade Biosciences announces first participant dosed in Phase 2 Juniper trial
2M ago
JBIO
Arthur He Reiterates Buy on Jade with Unchanged $45 Price Target Ahead of Key JADE101 Phase 1 Data
Premium
Ratings
Arthur He Reiterates Buy on Jade with Unchanged $45 Price Target Ahead of Key JADE101 Phase 1 Data
3M ago
JBIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >